早期检测出的前列腺癌的过度诊断与过度治疗。
Overdiagnosis and overtreatment of early detected prostate cancer.
作者信息
Bangma C H, Roemeling S, Schröder F H
机构信息
Department of Urology, Erasmus University Medical Centre, PO Box 2040, 3000 DR Rotterdam, Netherlands.
出版信息
World J Urol. 2007 Mar;25(1):3-9. doi: 10.1007/s00345-007-0145-z. Epub 2007 Feb 14.
Abstract
Early detection of prostate cancer is associated with the diagnosis of a considerable proportion of cancers that are indolent, and that will hardly ever become symptomatic during lifetime. Such overdiagnosis should be avoided in all forms of screening because of potential adverse psychological and somatic side effects. The main threat of overdiagnosis is overtreatment of indolent disease. Men with prostate cancer that is likely to be indolent may be offered active surveillance. Evaluation of active surveillance studies and validation of new biological parameters for risk assessment are expected.
摘要
前列腺癌的早期检测与相当一部分惰性癌症的诊断相关，这些癌症在一生中几乎不会出现症状。由于潜在的不良心理和躯体副作用，在所有形式的筛查中都应避免这种过度诊断。过度诊断的主要威胁是对惰性疾病的过度治疗。对于可能是惰性的前列腺癌男性患者，可以提供主动监测。预计将对主动监测研究进行评估，并验证用于风险评估的新生物学参数。
相似文献
1
Overdiagnosis and overtreatment of early detected prostate cancer.
World J Urol. 2007 Mar;25(1):3-9. doi: 10.1007/s00345-007-0145-z. Epub 2007 Feb 14.
2
Cancer overdiagnosis and overtreatment.
Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa.
3
Defining and predicting indolent and low risk prostate cancer.
Crit Rev Oncol Hematol. 2012 Aug;83(2):235-41. doi: 10.1016/j.critrevonc.2011.10.003. Epub 2011 Oct 26.
4
Should prostate-specific antigen screening be offered to asymptomatic men?
Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64.
5
Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.
6
Prostate cancer overdiagnosis and overtreatment.
Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi: 10.1097/MED.0b013e328360332a.
7
Active surveillance for prostate cancer: a review.
Arch Esp Urol. 2011 Oct;64(8):806-14.
8
Overdiagnosis and overtreatment of prostate cancer.
Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9.
9
Active surveillance: pitfalls to consider.
Arch Esp Urol. 2011 Oct;64(8):695-702.
10
Predictive models in diagnosing indolent cancer.
Cancer. 2009 Jul 1;115(13 Suppl):3100-6. doi: 10.1002/cncr.24347.
引用本文的文献
1
Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review.
J Pers Med. 2025 Jul 15;15(7):315. doi: 10.3390/jpm15070315.
2
Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study.
Future Oncol. 2025 Jul;21(17):2167-2176. doi: 10.1080/14796694.2025.2514930. Epub 2025 Jun 6.
3
Prostate cancer nomograms and their application in Asian men: a review.
Prostate Int. 2024 Mar;12(1):1-9. doi: 10.1016/j.prnil.2023.07.004. Epub 2023 Aug 4.
4
Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.
Sci Data. 2023 Nov 25;10(1):830. doi: 10.1038/s41597-023-02750-7.
5
Unveiling Disrupted Lipid Metabolism in Benign Prostate Hyperplasia, Prostate Cancer, and Metastatic Patients: Insights from a Colombian Nested Case-Control Study.
Cancers (Basel). 2023 Nov 18;15(22):5465. doi: 10.3390/cancers15225465.
6
Radiomic-based machine learning model for the accurate prediction of prostate cancer risk stratification.
Br J Radiol. 2023 Mar;96(1143):20220238. doi: 10.1259/bjr.20220238. Epub 2023 Jan 4.
7
Integrated analysis reveals prognostic value and progression-related role of AMIGO2 in prostate cancer.
Transl Androl Urol. 2022 Jul;11(7):914-928. doi: 10.21037/tau-21-1148.
8
The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer.
Front Artif Intell. 2021 Nov 16;4:769582. doi: 10.3389/frai.2021.769582. eCollection 2021.
9
Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly.
Mol Oncol. 2021 Oct;15(10):2565-2579. doi: 10.1002/1878-0261.13071. Epub 2021 Aug 30.
10
Can Prostate-Specific Antigen Density Be an Index to Distinguish Patients Who Can Omit Repeat Prostate Biopsy in Patients with Negative Magnetic Resonance Imaging?
Cancer Manag Res. 2021 Jul 8;13:5467-5475. doi: 10.2147/CMAR.S318404. eCollection 2021.
本文引用的文献
1
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
Eur Urol. 2007 Nov;52(5):1358-64. doi: 10.1016/j.eururo.2007.04.037. Epub 2007 Apr 20.
2
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
J Urol. 2007 Jan;177(1):107-12; discussion 112. doi: 10.1016/j.juro.2006.08.068.
3
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).
Int J Cancer. 2007 Feb 15;120(4):868-74. doi: 10.1002/ijc.22134.
4
Survival of patients with stage I lung cancer detected on CT screening.
N Engl J Med. 2006 Oct 26;355(17):1763-71. doi: 10.1056/NEJMoa060476.
5
Active surveillance versus radical treatment for favorable-risk localized prostate cancer.
Curr Treat Options Oncol. 2006 Sep;7(5):355-62. doi: 10.1007/s11864-006-0003-z.
6
Gleason score, age and screening: modeling dedifferentiation in prostate cancer.
Int J Cancer. 2006 Nov 15;119(10):2366-71. doi: 10.1002/ijc.22158.
7
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
J Urol. 2006 Apr;175(4):1286-90; discussion 1290. doi: 10.1016/S0022-5347(05)00706-8.
8
Tumour features in the control and screening arm of a randomized trial of prostate cancer.
Eur Urol. 2006 Jul;50(1):70-5. doi: 10.1016/j.eururo.2005.11.005. Epub 2005 Dec 19.
9
The effectiveness of screening for prostate cancer: a nested case-control study.
Arch Intern Med. 2006 Jan 9;166(1):38-43. doi: 10.1001/archinte.166.1.38.
10
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
J Urol. 2005 Dec;174(6):2154-7, discussion 2157. doi: 10.1097/01.ju.0000181213.07447.8f.
Zotero 插件